Raxar

Raxar®

Grepafloxacin, see there.
Mentioned in ?
References in periodicals archive ?
In 1999, the FDA and manufacturers withdrew one antibiotic, Raxar, from the market and greatly curtailed the use of another, Trovan, because of harmful side effects.
For the recalled antibiotic Raxar, the best information that I can find indicates that it was associated with 13 deaths from heart arrhythmia.
I do not have sufficient data to analyze the decision to withdraw Raxar and Trovan, and so I will not address that issue.
The eight drugs lately withdrawn were GlaxoSmithKline's Lotronex, for irritable bowel syndrome; American Home Products' Redux, a diet aid; the Bayer Corporation's Raxar, an antibiotic; Pfizer's Trovan, also an antibiotic; Roche's Posicor, a blood-pressure medication; Wyeth-Ayerst's Duract, a painkiller; Warner-Lambert's Rezulin, a diabetes drug; and, this spring, Organon's Raplon, an anesthetic.
Grepafloxacin, which was marketed as Raxar, was approved in 1997 for the treatment of community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, uncomplicated gonorrhea, and nongonococcal urethritis and cervicitis.
The drug, Raxar, is used to treat illnesses including pneumonia, bronchitis and some sexually transmitted infections.
Since 1997, more than a dozen prescription drugs, including Pondimin, Redux, Seldane, Posicor, Duracht, Hismanal, Raxar, Rezulin, Propulsid, Lotronex, Raplon and Baycol, with serious side effects, have been taken off the shelves.
New drugs such as Zyban - essentially an antidepressant repackaged and repatented as a smoking cessation aid - and respiratory anti-infective Raxar, are expected to provide further sales growth.
Tatsuo Higuchi; Phone +81-3-3292-0021) and GlaxoSmithKline plc (GSK) have resolved their longstanding dispute relating to the then Glaxo Wellcome's voluntary withdrawal from the market in October 1999 of grepafloxacin (generic name; trade names - RAXAR and VAXAR) by way of compensation payment by GSK to Otsuka.